FDA expands Bayer's Kerendia to type 1 diabetes-associated chronic kidney disease

The US FDA approved Bayer's Kerendia (finerenone) for treating chronic kidney disease (CKD) in adults with type 1 diabetes, marking its third indication. The approval is based on evidence that finerenone reduces urinary albumin-to-creatinine ratio, expected to slow kidney disease progression.

This Wire brief sits within Fusion42's coverage of Biotech.